Another interesting study, "neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma" by Walter Weder, Peter Kesten, Christian Taverna, Stefan Bodis, Didier Lardinois, Monika Jerman, Rolf A. Stahel calls - Journal of Clinical Oncology, Vol 22, No. 17 (September 1), 2004: pp. 3451 to 3457. Here is an excerpt: "Patients and Methods: Eligible patients had MPM done with clinical stage T1-3, N0-2 disease, M0 as a complete excision and WHO functional status of 0 to 2. The neoadjuvant chemotherapy three cycles of cisplatin 80 mg / m2 on day 1 and gemcitabine 1000 mg / m2 administered on days 1, 8 and 15, every 28 days. surgery had a full extrapleural pneumonectomy exist, including resection pericardium and diaphragm. postoperative radiation therapy should be considered in all patients.
RESULTS: Nineteen patients with MPM were enrolled in this pilot study. According to the European Organization for Research and Treatment of Cancer prognostic index, they were two patients in the good prognosis group and 17 patients in the poor prognosis group. The response rate to neoadjuvant chemotherapy was 32%. The main toxicity was thrombocytopenia. extrapleural pneumonectomy was performed in 16 patients without perioperative mortality. major surgical complications occurred in six patients, and all were successfully treated. Thirteen patients received postoperative radiotherapy. The median survival was 23 months. I Two patients were alive and free of disease 41 and 38 months after starting treatment.
CONCLUSION: In patients with potentially operable MPM, availability of active and well-tolerated chemotherapy that extrapleural be pneumonectomy performed safely after neoadjuvant chemotherapy in a center with experience and promising results in terms of survival in our pilot study required more research on the role of neoadjuvant chemotherapy in a multimodal approach. "
Another interesting study, "histone deacetylase inhibitor of the regulation of gene expression Bcl-XL leads to apoptotic cell death in mesothelioma." Cao XX Mohuiddin I, F Ece, McConkey DJ, Smythe WR called. . - M J Respir Cell Mol Biol 2001 November; 25 (5): 562-8. Here's an excerpt:. "Summary - has been shown to mesothelioma suppresses the anti-apoptotic Bcl-xL, but not Bcl-2 to cause the expression of Bcl-xl gene is a therapeutic target sodium butyrate (NAB) is a histone inhibitor protein deacetylase change in position of the protein expression of Bcl-2 family in other tumor types. cell lines mesothelioma (REN I-45) were exposed and viability NAB (colorimetric assay) and apoptosis (TUNEL, Hoechst staining, flow cytometry) were evaluated. affects the Bcl-2 protein, and Fas ligand caspases FAS were examined by Western blot analysis and functional assay. an evaluation of mRNA of Bcl-2 family (. mRNA) expression test RNase overexpressing clones mesothelioma Bcl-XL were created by cells transfer plasmids were sensitive to lower IQ in NAB (50) (REN, 0.3 mM; I-45, 1 mM) and showed apoptosis (cell percentage in G1 phase by flow cytometry [sub-G1.] REN, 38.5%; I-45, 30.9%). A significant decrease in the expression of bcl-xL was observed with BAK, BAX and BCL-2 unchanged, and transcription was confirmed in production decreased with Bcl-xl mRNA by selective exposure sodium butyrate. fas gata 3 mesothelial cells Fas expression of Fas ligand and sensitivity were unchanged. Caspases activation showed low. stable clones overexpressing Bcl-XL were proportionately resistant NAB effect. This study suggests that mesothelioma cells to cushion the Bcl-xL and anti-apoptotic gene protein expression related apoptosis induction sensitive. An additional study the therapeutic value of directing the expression of Bcl-XL gene in mesothelioma is justified. "
Another interesting study is called, "antibody Ber-EP4 as discriminant in the differential diagnosis of malignant mesothelioma Versus adenocarcinoma" - September 1991 - Volume 15 - Issue 8 - American Journal of Clinical Pathology Sheibani, Khalil MD Shin Sung SMD Kezirian, Janice BA. White, Lawrence MMD Here is an excerpt:. "Summary - The pathological diagnosis of malignant mesothelioma is often difficult, even with the advantage of special studies such as immunohistochemistry, electron microscopy and immunohistochemistry Ber-EP4 with new tags reliable epithelial monoclonal antibodies are characterized, but not reactive mesothelial cells . studied Ber-EP4 in tissue sections fixed in formalin, paraffin 115 mesotheliomas and 83 adenocarcinomas. Although 72 cases (87%) were positive adenocarcinoma of Ber-EP4, one (1%) was reactive https://www.ehealthinsurance.com/ mesothelioma. the only adenocarcinomas, point pectoris is not (eight of the 25 cases, nonreactive) and kidneys (three nonreactive cases). the pattern of staining in the positive adenocarcinomas was intense and usually membranous, however, a small cytoplasmic staining was observed additional in many cases. reactivity was diffuse in 59 cases in 13 cases, and focal length. the results of our study indicate that the Ber-EP4 antibody may be useful in the differential diagnosis of mesothelioma compared with adenocarcinoma, especially if only in formalin-fixed tissues. "
All owe gratitude to these fine researchers. If you find any of these interesting excerpts, please read the studies in their entirety.